Gail Boxer Marcus Sells 4,000 Shares of Natera, Inc. (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA - Get Free Report) Director Gail Boxer Marcus sold 4,000 shares of Natera stock in a transaction dated Tuesday, June 10th. The stock was sold at an average price of $164.44, for a total value of $657,760.00. Following the sale, the director now directly owns 5,704 shares in the company, valued at approximately $937,965.76. The trade was a 41.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Gail Boxer Marcus also recently made the following trade(s):

• On Thursday, May 1st, Gail Boxer Marcus sold 4,000 shares of Natera stock. The stock was sold at an average price of $151.61, for a total value of $606,440.00.
• On Tuesday, April 1st, Gail Boxer Marcus sold 4,000 shares of Natera stock. The stock was sold at an average price of $140.78, for a total value of $563,120.00.

Natera Stock Performance

NTRA stock traded down $2.41 during midday trading on Thursday, reaching $164.35. The company had a trading volume of 1,102,057 shares, compared to its average volume of 1,406,706. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. The stock has a 50 day moving average price of $153.38 and a 200 day moving average price of $158.62. Natera, Inc. has a fifty-two week low of $92.14 and a fifty-two week high of $183.00. The firm has a market capitalization of $22.44 billion, a PE ratio of -93.38 and a beta of 1.74.

Natera (NASDAQ:NTRA - Get Free Report) last issued its earnings results on Thursday, May 8th. The medical research company reported ($0.50) EPS for the quarter, beating analysts' consensus estimates of ($0.59) by $0.09. The company had revenue of $501.83 million during the quarter, compared to the consensus estimate of $446.68 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. Natera's quarterly revenue was up 36.5% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.56) earnings per share. Analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on NTRA. Morgan Stanley boosted their price objective on Natera from $176.00 to $185.00 and gave the company an "overweight" rating in a report on Wednesday, March 5th. UBS Group boosted their price objective on Natera from $211.00 to $218.00 and gave the company a "buy" rating in a report on Friday, May 9th. Canaccord Genuity Group reissued a "buy" rating and issued a $180.00 price objective on shares of Natera in a report on Wednesday, February 26th. BTIG Research reissued a "buy" rating on shares of Natera in a report on Friday, February 28th. Finally, Royal Bank of Canada began coverage on Natera in a report on Thursday, March 13th. They issued an "outperform" rating and a $251.00 price objective for the company. One analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $184.63.

Hedge Funds Weigh In On Natera

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Principal Securities Inc. boosted its position in shares of Natera by 20.7% during the fourth quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock worth $54,000 after buying an additional 59 shares during the period. Gladstone Institutional Advisory LLC boosted its position in shares of Natera by 1.7% during the fourth quarter. Gladstone Institutional Advisory LLC now owns 3,629 shares of the medical research company's stock worth $574,000 after buying an additional 61 shares during the period. Fulton Bank N.A. boosted its position in shares of Natera by 2.0% during the first quarter. Fulton Bank N.A. now owns 3,652 shares of the medical research company's stock worth $516,000 after buying an additional 71 shares during the period. Compound Planning Inc. boosted its position in shares of Natera by 4.2% during the first quarter. Compound Planning Inc. now owns 1,914 shares of the medical research company's stock worth $271,000 after buying an additional 78 shares during the period. Finally, QRG Capital Management Inc. boosted its position in shares of Natera by 1.5% during the first quarter. QRG Capital Management Inc. now owns 5,417 shares of the medical research company's stock worth $766,000 after buying an additional 81 shares during the period. 99.90% of the stock is currently owned by institutional investors and hedge funds.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.